Price Don’t Lie: What’s Next for Chimerix Inc After Today’s Significant Increase?

Price Don't Lie: What's Next for Chimerix Inc After Today's Significant Increase?

The stock of Chimerix Inc (NASDAQ:CMRX) is a huge mover today! About 383,721 shares traded hands. Chimerix Inc (NASDAQ:CMRX) has declined 30.17% since April 4, 2016 and is downtrending. It has underperformed by 31.26% the S&P500.
The move comes after 8 months positive chart setup for the $175.62M company. It was reported on Nov, 4 by We have $6.65 PT which if reached, will make NASDAQ:CMRX worth $131.72M more.

Chimerix Inc (NASDAQ:CMRX) Ratings Coverage

Out of 7 analysts covering Chimerix Inc (NASDAQ:CMRX), 2 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 29% are positive. Chimerix Inc has been the topic of 16 analyst reports since August 5, 2015 according to StockzIntelligence Inc. On Tuesday, February 23 the stock rating was downgraded by Barclays Capital to “Equal-Weight”. The stock has “Outperform” rating given by FBR Capital on Tuesday, August 18. On Thursday, December 17 the stock rating was initiated by UBS with “Buy”. Brean Capital maintained the shares of CMRX in a report on Thursday, August 6 with “Buy” rating. The stock has “Overweight” rating given by Piper Jaffray on Monday, December 28. JP Morgan downgraded Chimerix Inc (NASDAQ:CMRX) on Tuesday, December 29 to “Neutral” rating. As per Thursday, September 3, the company rating was initiated by Citigroup. The rating was downgraded by Morgan Stanley to “Underweight” on Tuesday, February 23. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Monday, October 5. On Monday, December 28 the stock rating was downgraded by FBR Capital to “Mkt Perform”.

According to Zacks Investment Research, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina.”

Insitutional Activity: The institutional sentiment decreased to 0.8 in 2016 Q2. Its down 0.27, from 1.07 in 2016Q1. The ratio is negative, as 23 funds sold all Chimerix Inc shares owned while 37 reduced positions. 16 funds bought stakes while 32 increased positions. They now own 30.87 million shares or 5.26% less from 32.59 million shares in 2016Q1.
Zurcher Kantonalbank (Zurich Cantonalbank) owns 896 shares or 0% of their US portfolio. Moreover, Gsa Cap Prns Llp has 0.02% invested in Chimerix Inc (NASDAQ:CMRX) for 88,931 shares. Blackrock Fund Advsrs reported 1.69M shares or 0% of all its holdings. Swiss National Bank & Trust has 0% invested in the company for 65,800 shares. Natl Bank Of Montreal Can owns 24,417 shares or 0% of their US portfolio. Geode Mngmt Ltd Liability Co owns 289,897 shares or 0% of their US portfolio. Nationwide Fund accumulated 0% or 30,079 shares. D E Shaw & Inc accumulated 83,679 shares or 0% of the stock. Teacher Retirement Systems Of Texas has 5,759 shares for 0% of their US portfolio. Wells Fargo & Mn holds 0% of its portfolio in Chimerix Inc (NASDAQ:CMRX) for 17,275 shares. Fred Alger Mgmt last reported 36,150 shares in the company. Blackrock Inc holds 0% or 4,086 shares in its portfolio. Alpinvest Prtn Bv holds 0.16% or 20,769 shares in its portfolio. Glenmede Tru Na accumulated 6,992 shares or 0% of the stock. The California-based Los Angeles Cap Management Equity has invested 0% in Chimerix Inc (NASDAQ:CMRX).

Insider Transactions: Since May 10, 2016, the stock had 3 buys, and 1 sale for $241,560 net activity. MARIO ERNEST bought $121,169 worth of Chimerix Inc (NASDAQ:CMRX) on Tuesday, May 10. Berrey M Michelle had bought 22,417 shares worth $100,226 on Monday, August 29. LEONARD JOHN M. had sold 5,000 shares worth $25,163.

More important recent Chimerix Inc (NASDAQ:CMRX) news were published by: which released: “Chimerix Inc. NASDAQ: CMRX” on April 13, 2013, also published article titled: “Chimerix Inc. CMRX (US: Nasdaq)”, published: “Here’s Why Chimerix Inc Jumped 14.3% in April” on May 06, 2016. More interesting news about Chimerix Inc (NASDAQ:CMRX) was released by: and their article: “Why Chimerix Inc. Is Up Big Today” with publication date: January 19, 2016.

CMRX Company Profile

Chimerix, Inc. (Chimerix), incorporated on April 7, 2000, is a biopharmaceutical company. The Firm is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment